Company / Shareholders' Equity
Lipocine Inc. Shareholders' Equity History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$21.0M
FY2025
5-year range
$15.3M / $45.6M
FY2021-FY2025
Trend
+3.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity returned to growth in FY2025 after 2 years of decline, reaching $21M.
Based on SEC 10-K filings.
$21M in FY2025 with a 5-year CAGR of +27.3%.
Declined from $36M to $21M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -22.8%
- 5-Year CAGR
- +27.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +27.3%, indicating consistent growth.
- In FY2025, shareholders' equity increased 3.1% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2013.
Company context
Key Data Points
- Altman Z-Score -1.16 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $21.0M | +3.1% |
| FY2024 | $20.4M | -42.8% |
| FY2023 | $35.6M | -21.8% |
| FY2022 | $45.6M | +197.0% |
| FY2021 | $15.3M | +144.0% |
| FY2020 | $6.3M | -33.3% |
| FY2019 | $9.4M | -50.3% |
| FY2018 | $19.0M | +257.0% |
| FY2013 | $5.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026